

# Dengue: A Growing Problem With New Interventions

Joshua M. Wong, MD,<sup>a,b</sup> Laura E. Adams, DVM, MPH,<sup>b</sup> Anna P. Durbin, MD,<sup>c</sup> Jorge L. Muñoz-Jordán, PhD,<sup>b</sup> Katherine A. Poehling, MD, MPH,<sup>d</sup> Liliana M. Sánchez-González, MD, MPH,<sup>b</sup> Hannah R. Volkman, PhD, MPH,<sup>b</sup> Gabriela Paz-Bailey, MD, PhD, MSc<sup>b</sup>

Dengue is the disease caused by 1 of 4 distinct, but closely related dengue viruses (DENV-1–4) that are transmitted by *Aedes* spp. mosquito vectors. It is the most common arboviral disease worldwide, with the greatest burden in tropical and sub-tropical regions. In the absence of effective prevention and control measures, dengue is projected to increase in both disease burden and geographic range. Given its increasing importance as an etiology of fever in the returning traveler or the possibility of local transmission in regions in the United States with competent vectors, as well as the risk for large outbreaks in endemic US territories and associated states, clinicians should understand its clinical presentation and be familiar with appropriate testing, triage, and management of patients with dengue. Control and prevention efforts reached a milestone in June 2021 when the Advisory Committee on Immunization Practices (ACIP) recommended Dengvaxia for routine use in children aged 9 to 16 years living in endemic areas with laboratory confirmation of previous dengue virus infection. Dengvaxia is the first vaccine against dengue to be recommended for use in the United States and one of the first to require laboratory testing of potential recipients to be eligible for vaccination. In this review, we outline dengue pathogenesis, epidemiology, and key clinical features for front-line clinicians evaluating patients presenting with dengue. We also provide a summary of Dengvaxia efficacy, safety, and considerations for use as well as an overview of other potential new tools to control and prevent the growing threat of dengue.

Full article can be found online at [www.pediatrics.org/cgi/doi/10.1542/peds.2021-055522](http://www.pediatrics.org/cgi/doi/10.1542/peds.2021-055522)

## abstract



<sup>a</sup>Epidemic Intelligence Service, Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, Georgia; <sup>b</sup>Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico; <sup>c</sup>Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; and <sup>d</sup>Wake Forest School of Medicine, Winston-Salem, North Carolina

Drs Wong, Adams, and Paz-Bailey conceptualized and designed the structure of the review, drafted portions of the initial manuscript, and reviewed and revised the manuscript; Drs Durbin, Muñoz-Jordán, Sánchez-González, and Volkman drafted portions of the initial manuscript and reviewed and revised the manuscript; Dr Poehling reviewed and revised the manuscript; and all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

DOI: <https://doi.org/10.1542/peds.2021-055522>

Accepted for publication Mar 11, 2022

Address correspondence to Joshua M. Wong, MD, Epidemiology Team, Dengue Branch, 1324 Calle Canada, San Juan, PR 00979. E-mail: [nof9@cdc.gov](mailto:nof9@cdc.gov)


PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2022 by the American Academy of Pediatrics

**FUNDING:** No external funding.

**CONFLICT OF INTEREST DISCLOSURES:** Dr Durbin is a scientific advisor to Merck & Co on dengue vaccine development. The other authors have no conflicts of interest to disclose.

**To cite:** Wong JM, Adams LE, Durbin AP, et al. Dengue: A Growing Problem With New Interventions. *Pediatrics*. 2022;149(6):e2021055522



**FIGURE 1** Map showing the risk of dengue by country as of 2020. “Frequent or Continuous” risk indicates that there are either frequent outbreaks or ongoing transmission. “Sporadic or Uncertain” indicates that risk is either variable and unpredictable or that data from that country are not available. For updated information, visit <https://www.cdc.gov/dengue/areaswithrisk/around-the-world.html>.


Dengue is the disease caused by 4 closely related but distinct viruses, dengue virus 1–4 (DENV-1–4), referred to as virus types or serotypes. DENVs are most commonly transmitted by the bite of an infected female *Aedes* spp. mosquito. It is the most common arboviral disease globally, with an estimated 390 million dengue virus infections and 96 million symptomatic cases annually.<sup>1</sup> Global incidence has almost doubled in the last 3 decades and is expected to continue growing in Asia, sub-Saharan Africa, and Latin America. About half of the global population now lives in areas that are suitable for dengue transmission (Fig 1).<sup>2,3</sup> Historically, the highest burden of dengue has been in children, adolescents, and young adults.<sup>4</sup> In 2019, countries across the Americas reported more than 3 million dengue cases, the highest number ever recorded,<sup>5</sup> with a greater proportion of severe dengue cases and increased mortality in the pediatric population of children aged 5 to 9 years.<sup>6</sup> Dengue is increasingly common as an etiology of fever in international travelers<sup>7</sup> and has been reported as the leading febrile disease etiology for

travelers from some endemic regions during epidemic years.<sup>8</sup> In addition to circulation of all four DENVs worldwide, surveillance of returning travelers with dengue has demonstrated high genetic diversity among circulating DENV genotypes within serotypes, with potential implications for immune or vaccine escape.<sup>9,10</sup>

## A GROWING PROBLEM IN THE UNITED STATES

Increasing numbers of dengue cases in the United States are a growing concern. In parts of the United States and freely associated states with endemic dengue transmission, including American Samoa, Puerto Rico, US Virgin Islands, Federated States of Micronesia, Republic of Marshall Islands, and the Republic of Palau, dengue outbreaks can be explosive, overwhelming the health care system capacity. In Puerto Rico, the largest US territory where dengue is endemic, the highest incidence of dengue cases and hospitalizations from 2010 to 2020 occurred among children aged 10 to 19 years.<sup>11</sup> For the same period, confirmed dengue cases ranged from a minimum of 3 cases in 2018 to a maximum of 10 911 cases in 2010,<sup>11</sup> although suspected case counts during outbreak years were considerably higher.<sup>12</sup>

Although local dengue transmission does not occur frequently in most states, increasing numbers of US travelers<sup>13</sup> with dengue have been reported in recent years, with a record 1475 cases in 2019, more



**FIGURE 2** Annual number of travel-associated cases of dengue reported into ArboNET, the national arboviral surveillance system managed by the CDC, from all US jurisdictions from 2010 to 2019 ( $n = 6967$ ).


than 50% higher than the previous peak in 2016 (Fig 2).<sup>14</sup> Viremia among travel-associated dengue cases can also result in focal outbreaks in nonendemic areas, with competent mosquito vectors for dengue present in approximately half of all US counties.<sup>15</sup> Local dengue cases have been reported in multiple states in recent years, including 70 cases in Florida in 2020,<sup>14</sup> 200 cases in Hawaii in 2015,<sup>14</sup> and 53 cases in Texas in 2013.<sup>16</sup>

### ENVIRONMENTAL FACTORS CONTRIBUTING TO DENGUE AS A PUBLIC HEALTH THREAT

In dengue-endemic areas, environmental factors such as

standing water where mosquitoes lay eggs, poor housing quality, lack of air conditioning, and climatic factors (ie, temperature, precipitation, and humidity) increase the abundance, distribution, and risk of exposure to *Aedes aegypti*, the main vector responsible for dengue transmission, or other *Aedes* spp. mosquitoes that can also transmit dengue.<sup>2,17-21</sup> Climate change is predicted to further increase the population at risk for dengue primarily through increased transmission in currently endemic areas and secondarily through expansion of the geographic range of *Aedes* spp. mosquitoes (Fig 3).<sup>2,22</sup> Urbanization, increasing population density, human migration, and growing social and environmental

factors associated with poverty and forced displacement are also expected to drive the increase in dengue incidence and force of infection globally.<sup>21,23-26</sup> Travel is an important driver of dengue expansion by introducing dengue into nonendemic areas with competent vectors<sup>13,23</sup> or by introducing new serotypes into endemic areas naive to the new serotype, thereby increasing the risk for antibody-dependent enhancement (ADE) and severe disease.<sup>27,28</sup> Combined environmental effects of poverty and the increased scale and rapidity of human movement can also increase the risk for dengue.<sup>24,29</sup> The combined environmental effects of climate change, urbanization,



**FIGURE 3**

A-C, Projections of average trends in environmental suitability for dengue transmission from 2015 to 2020, 2020 to 2050, and 2050 to 2080. D-F, Areas with expansion or contraction of the *Aedes* vector range over the same time periods. (Reprinted with permission from Messina JP, Brady OJ, Golding N, Kraemer MUG, Wint GRW, Ray SE, et al. The current and future global distribution and population at risk of dengue. *Nature Microbiology*. 2019;4(9):1510.)

poverty, and human migration together expand the threat of dengue for both individuals and public health systems in the future.

### PATHOGENESIS


DENVs belong to the genus *Flavivirus* in the family *Flaviviridae*. Because there are 4 dengue serotypes, individuals living in endemic areas can be infected up to 4 times in their life. Although most dengue virus infections are asymptomatic or only cause mild disease, severe disease can occur and is characterized by plasma leakage, a pathophysiologic process by which the protein rich fluid component of blood leaks into the surrounding tissue, leading to extravascular fluid accumulation resulting in shock, coagulopathy, or end organ impairment.<sup>30,31</sup>

Infection with 1 dengue serotype induces life-long protection against symptomatic infection with that specific serotype (homotypic immunity)<sup>32,33</sup> and induces only short-term cross-reactive protection from disease to the other serotypes (heterotypic immunity) for several months to years.<sup>34,35</sup> Older children and adults experiencing their second

dengue infection are at the highest risk for severe disease because of ADE. ADE has also been observed among infants, in that infants born to mothers with previous dengue virus infection had the lowest risk for dengue shortly after birth and a period of higher risk for severe disease approximately 4 to 12 months after birth, followed by a decrease in risk for severe disease from approximately 12 months after birth.<sup>36</sup> The initial period of lowest risk was correlated with high levels of passively acquired maternal dengue antibodies immediately after birth, and the period of enhanced risk with a decline in these antibodies to subneutralizing levels. After further degradation of these maternal antibodies, there was neither protection from dengue afforded by high levels of antibodies postnatally nor enhanced risk of dengue and severe disease from the intermediate levels of antibodies.<sup>37</sup> Later work showed that lower heterotypic antibody titers are ineffective at neutralizing the virions but still bind them, facilitating binding to Fcγ receptors on circulating monocyte cells, and result in higher viremia than in primary infections (Fig 4).<sup>38</sup> The

feared sequela of plasma leakage is believed to be mediated by high levels of DENV nonstructural protein 1 (NS1), a key protein for viral replication and pathogenesis,<sup>39,40</sup> that damages endothelial glycocalyxes and disrupts endothelial cell junctions.<sup>41,42</sup> Cell-mediated immunity through dengue-specific CD8 T cells is thought to protect against ADE and severe disease.<sup>43,44</sup>

Although ADE occurs in infants due to the interaction between maternal antibodies and primary infection, it is also explanatory for severe disease in older children and adults where the heterotypic antibodies produced after a primary dengue infection will wane over time to subneutralizing levels, resulting in the highest risk for severe disease with secondary infection. Following secondary infection, potent cross-neutralizing/multitypic antibodies are induced that then protect against severe disease in tertiary and quaternary infections.<sup>45,46</sup> Although the risk of severe dengue is highest with secondary infection, it can also occur in primary, tertiary, and quaternary infections, and possibly following Zika virus



**FIGURE 4**

The proposed mechanism of antibody-dependent enhancement with heterotypic antibodies binding to the dengue viruses and entering monocytes through Fcγ receptors. Viral replication occurs in the infected monocyte and releases high levels of virus and dengue virus NS1 protein, which, in turn, lead to increased vascular permeability contributing to severe disease. (Reprinted with permission from Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. *Nature Reviews Microbiology*. 2007;5(7):524.)

**TABLE 1** Classification of Dengue Severity and Case Management<sup>51,134,135</sup>

Dengue without Warning Signs	Dengue with Warning Signs	Severe Dengue
<p>Any patient who has traveled to or lives in a dengue-endemic area and presents with fever (typically 2–7 d in duration) and at least 1 of the following:</p> <ul style="list-style-type: none"> <li>• Nausea</li> <li>• Vomiting</li> <li>• Rash</li> <li>• Aches and pains (headache, eye pain, muscle ache or joint pain)</li> <li>• Positive tourniquet test</li> <li>• Leukopenia</li> </ul>	<p>Any patient who meets the criteria for dengue without warning signs and, typically around the time of defervescence, has at least 1 of the following:</p> <ul style="list-style-type: none"> <li>• Severe abdominal pain or tenderness</li> <li>• Persistent vomiting</li> <li>• Clinical extravascular fluid accumulation</li> <li>• Postural hypotension</li> <li>• Any mucosal bleeding</li> <li>• Lethargy/restlessness</li> <li>• Liver enlargement</li> <li>• Progressive increase in hematocrit (ie, hemoconcentration) with concurrent rapid decrease in platelet count</li> </ul>	<p>Any patient meeting the criteria for dengue with or without warning signs and has at least 1 of the following:</p> <ul style="list-style-type: none"> <li>• Severe plasma leakage leading to shock or extravascular fluid accumulation with respiratory distress.</li> <li>• Severe bleeding from the gastrointestinal tract or vagina requiring medical intervention such as intravenous fluid resuscitation or blood transfusion.</li> <li>• Severe organ impairment such as elevated transaminases <math>\geq 1000</math> IU/L, impaired consciousness, or heart impairment.</li> </ul>
Case Management		
Outpatient management	Hospital or observation admission	ICU admission

infection.<sup>47,48</sup> Identifying cases of severe dengue and understanding the pathogenesis of disease severity is an active area of research with important implications for future vaccines and interventions.<sup>49</sup>

## CLINICAL CONSIDERATIONS

### Presentation and Evaluation

DENV infections have a wide range of presentations from asymptomatic infection (approximately 75% of all infections<sup>50</sup>) to mild to moderate febrile illness to severe disease with associated coagulopathy, shock, or end organ impairment (Table 1).<sup>30,31</sup> Symptomatic infections most commonly present with fever accompanied by nonspecific symptoms such as nausea, vomiting, rash, myalgias, arthralgias, retroorbital pain, headache and/or leukopenia.<sup>51</sup> Severe disease develops in as many as 5% of all patients with dengue, although certain populations such as infants aged  $\leq 1$  year, pregnant individuals, and adults aged  $\geq 65$  years, or individuals with specific underlying

conditions such as diabetes, class III obesity, hypertension, asthma, coagulopathy, gastritis or peptic ulcer disease, hemolytic disease, chronic liver disease, anticoagulant therapy, or kidney disease, are at increased risk of severe disease.<sup>52,53</sup> In all patients with dengue, warning signs are specific clinical findings that can predict progression to severe disease and are used by the World Health Organization (WHO) to help clinicians in triage and management decisions. Dengue warning signs include abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy or restlessness, liver enlargement of  $>2$  cm, and increasing hematocrit concurrent with rapid decrease in platelet count (Table 1).<sup>52</sup>

Although warning signs are useful for evaluating patients with a high suspicion of dengue (for example, during an outbreak), they are not intended to differentiate dengue from other infectious and noninfectious diseases such as

influenza, coronavirus disease 2019, malaria, Zika, measles, leptospirosis, rickettsial disease, typhoid, Kawasaki, or idiopathic thrombocytopenic purpura. Because prompt recognition and early treatment of dengue can greatly reduce morbidity and mortality,<sup>54,55</sup> clinicians practicing in the United States and other nonendemic areas should keep dengue in the differential diagnosis for febrile illness in travelers and in areas with competent mosquito vectors.

### Diagnostic Testing for Symptomatic DENV Infection

For symptomatic dengue patients, nucleic acid amplification tests (NAATs) on serum, plasma, or whole blood detect DENV RNA during the first 7 days of illness with high sensitivity and specificity.<sup>56,57</sup> Likewise, NS1 antigen can also be detected within the first 7 days and provides confirmatory evidence of DENV infection.<sup>58</sup> For patients with a negative NAAT or patients presenting more than 7 days after symptom onset, a positive anti-

DENV immunoglobulin M (IgM) can suggest recent infection, although with less certainty than NAAT or NS1 testing, owing to cross-reactivity with other flaviviruses. Notably, Zika virus is a flavivirus that has been transmitted in most countries where DENV transmission is present.<sup>59</sup> In patients from areas with ongoing transmission of another flavivirus (eg, Zika virus) and whose only evidence of dengue is a positive anti-DENV IgM test, plaque reduction neutralization tests (PRNT) quantifying virus-specific neutralizing antibody titers can distinguish DENV from other flaviviruses, in some but not all cases. PRNTs, however, are rarely available in clinical laboratories and typically do not provide results within a timeframe that is meaningful for clinicians managing acute disease. PRNT's may be valuable in circumstances where confirming the diagnosis may have important clinical implications, such as distinguishing dengue from a Zika virus infection in a pregnant individual, or epidemiologic implications for a region, such as distinguishing yellow fever from dengue.<sup>60,61</sup>

The US Food and Drug Administration (FDA) has approved a NAAT for use on serum and whole blood, an NS1 antigen enzyme-linked immunosorbent assay test in serum, and an IgM enzyme-linked immunosorbent assay in serum.<sup>56,59,62-64</sup> Other non-FDA-approved tests for DENV infection are used in clinical practice and are commercially available at accredited laboratories.

### Treatment

Although several medications have been explored as potential therapeutics for dengue, none have demonstrated a reduction in viremia, clinical manifestations, or complications.<sup>30,65</sup> As such, dengue

treatment focuses on supportive care. Clinicians should evaluate all patients at presentation and in follow-up for warning signs or other signs and symptoms of severe dengue (Table 1). Most patients without warning signs may be treated as outpatients, whereas patients at high risk of progression to severe disease based on age or underlying conditions, patients with warning signs, or patients with challenging social circumstances should be evaluated for observation or inpatient management.<sup>66</sup>

For outpatients, fever can be controlled with acetaminophen and physical cooling measures; because of the risk of bleeding and thrombocytopenia, aspirin and nonsteroidal anti-inflammatory drugs are not recommended. Early, abundant oral hydration has been associated with lower hospitalization rates in children with dengue and is a key component of outpatient dengue care.<sup>67-69</sup>

Early recognition of warning signs or severe dengue is essential for the prompt initiation of systematic intravenous fluid management to restore intravascular volume and avoid related complications and disease progression.<sup>30,70</sup> Large-volume resuscitation with isotonic solutions is recommended for patients in shock.<sup>54,71-73</sup> Fluid management in dengue requires continuous clinical and laboratory monitoring and rate adjustments to maintain adequate volume but also to prevent fluid overload. Mortality for untreated severe dengue can be 13% or higher<sup>74,75</sup> but can be reduced to <1% with early diagnosis and appropriate management.<sup>55</sup> Detailed information on systematic fluid management is provided in the current WHO, Pan American Health Organization, and Centers for Disease Control and Prevention (CDC) guidelines.<sup>72,73,76</sup>

Corticosteroids,<sup>77</sup> immunoglobulins,<sup>78</sup> and prophylactic platelet transfusions<sup>79,80</sup> have not demonstrated benefits in patients with dengue and are not recommended.

### Traditional Prevention Measures

Prevention of dengue involves protection against mosquito bites. Travelers to and residents of endemic areas can prevent mosquito bites by using US Environmental Protection Agency–approved insect repellents (<https://www.epa.gov/insect-repellents>) and wearing clothing that covers arms and legs. The use of screened windows and doors, air conditioning, and bed nets has been associated with protection from dengue infections.<sup>24,81-87</sup> Sites where mosquitoes lay eggs should be eliminated by emptying and scrubbing, covering, or eliminating standing water receptacles around the house. Mosquito bite prevention measures are important for all persons at risk for dengue, including vaccinated children.

### Novel Vector Control Efforts

Traditional vector control interventions can be time consuming and inefficient.<sup>88</sup> Furthermore, chemical control is limited by widespread insecticide resistance in endemic areas.<sup>89</sup> In response to these challenges, novel vector control methods have been developed including several strategies employing genetically modified mosquito technology and 2 strategies using *Wolbachia pipiensis*, an intracellular bacterium found in about 60% of all insects but not commonly found in wild *Aedes* mosquitoes.<sup>90-92</sup>

The first strategy utilizing *Wolbachia* is *Wolbachia*-mediated suppression, in which a reduction in wild populations of *Aedes* mosquitoes is achieved by continuously releasing infected

males into the environment.<sup>93</sup> When the infected males mate with wild females, the resultant eggs are inviable, leading to a decline in wild mosquito populations.<sup>94</sup> Some reports have documented reduction of the wild populations that can transmit dengue by more than 80%.<sup>95,96</sup>

The second strategy is the *Wolbachia* replacement method, where both *Wolbachia*-infected male and female mosquitoes are released. Because *Wolbachia* is transmitted maternally, the mosquitoes that hatch from the eggs of infected females will be infected with *Wolbachia* from birth.<sup>97,98</sup> *Wolbachia* infection in female mosquitoes taking a bloodmeal reduces transmission of arboviruses, including dengue, chikungunya, and Zika. This method has demonstrated significant reductions of nearly 80% for the outcomes of dengue infection and related hospitalizations in areas where it has been implemented<sup>99</sup> and is currently being deployed in several countries.

Extensive studies have found no evidence of *Wolbachia* in the plants,

soil, or other insects in contact with the *Wolbachia*-infected mosquitoes or any evidence of *Wolbachia* transmission to humans from the bites of infected mosquitoes, indicating that safety risks from *Wolbachia*-based interventions for humans and the environment are low.<sup>100</sup>

### Current Dengue Vaccines

ACIP made the first recommendation of a dengue vaccine (Dengvaxia) for use in the United States on June 24, 2021, marking an historic moment for dengue control following decades of global efforts to develop a safe and effective vaccine. Two other vaccines, TAK-003 developed by Takeda and TV003 developed by the National Institutes of Health, are in late-stage trials with efficacy results published or expected in 2022.

### Principles of Live-Attenuated Dengue Vaccines

All 3 are live vaccines and contain 4 different attenuated vaccine viruses (tetravalent) targeting each of the dengue virus serotypes (Fig 5) with the goal of achieving balanced protective immunity against all

4 serotypes, in both those who are DENV naïve and those who have been previously infected with DENV. Vaccine virus replication (infectivity) of each vaccine serotype after immunization will lead to antigenic stimulation, which then results in homotypic immunity. Infectivity by vaccine virus serotype differed among the 3 vaccines (Table 2).

These differences in vaccine serotype specific infectivity mirrored the induction of neutralizing homotypic antibody titers. Dengvaxia induced approximately 70% homotypic antibody for DENV-4 but <50% for DENV-1, DENV-2, and DENV-3.<sup>101</sup> Antibodies induced by TAK-003 were 83% homotypic for DENV-2 and 5%, 12%, and 27% homotypic for DENV-1, DENV-3, and DENV-4, respectively.<sup>102</sup> TV003 induced a balanced homotypic antibody response to DENV-1 (62%), DENV-2 (76%), DENV-3 (86%), and DENV-4 (100%).<sup>103</sup> Although homotypic antibody titers are associated with serotype specific vaccine efficacy, immune correlates that reliably predict vaccine efficacy have not yet been identified and remain an area of active research.<sup>46</sup>

## DENGVAXIA

### History of Dengvaxia

Dengvaxia uses a 3-dose schedule with each dose given 6 months apart (at months 0, 6, and 12). It was developed by Washington and St Louis Universities and Acambis and licensed to Sanofi Pasteur in the 2000s, entered phase 3 trials in the 2010s, and was first recommended by WHO in 2016 for persons aged 9 years and older living in highly endemic areas. Long-term follow-up data (over 5 years) from the phase 3 trials and further analyses of the efficacy results<sup>104-107</sup> demonstrated that children with evidence of previous DENV infection were protected from virologically confirmed dengue illness, including

## Live attenuated dengue vaccines




	Dengvaxia (Sanofi Pasteur)	TAK-003 (Takeda)	TV003 (NIH/Butantan)
Status	Licensed	Phase 3	Phase 3
# Doses	3 doses over 12 months (0, 6, 12)	2 doses (0, 3 months)	Single dose
Indicated age	9 - 45	Phase 3 age range 4 - 16	Phase 3 age range 2 - 59
Other	Requires documented previous DENV immunity	?	?
Construct			
Dengue proteins	8	16	32

FIGURE 5

Key features of the 3 live attenuated dengue vaccines. Each DENV serotype is represented by a color (DENV-1 = green, DENV-2 = gray, DENV-3 = crimson, and DENV-4 = blue). Dengvaxia is comprised of 4 chimeric viruses in which the prM and E of each DENV serotype replaces those of yellow fever 17D (yellow).<sup>132</sup> TAK-003 is comprised of 1 full-length DENV-2 and 3 chimeric viruses (prM and E of DENV-1, DENV-3, and DENV-4 on a DENV-2 background).<sup>133</sup> TV003 is comprised of 3 full-length DENV and 1 chimeric virus.<sup>123</sup> The total number of dengue proteins in each vaccine is also shown.

**TABLE 2** Percentage of Vaccine Recipients with Detectable Vaccine Virus Serotype by RT-PCR after a Single Dose of the Indicated Vaccine in Persons without Previous Dengue Virus Infections

	DENV-1	DENV-2	DENV-3	DENV-4
Dengvaxia (n = 95) <sup>136</sup>	7.4	0	12.6	44.2
TAK-003 (n = 74) <sup>137</sup>	0	68.9	0	0
TV003 (n = 36) <sup>138</sup>	63.9	69.4	52.8	52.8

Data are presented as percentage.

severe dengue if they were vaccinated with Dengvaxia. However, risk of hospitalization for dengue and severe dengue was increased among children without previous dengue infection who were vaccinated with Dengvaxia and had a subsequent dengue infection in the years after vaccination. In children without a previous dengue infection, the vaccine acts as a silent primary dengue infection resulting in a “secondary-like” infection upon their first infection with wild-type DENV and an increased risk of severe disease due to ADE (Fig 6).<sup>108,109</sup> After these findings, WHO revised their recommendations for the

vaccine to only be given to children with laboratory-confirmed evidence of a past infection. Following WHO’s recommendation, the FDA licensed Dengvaxia in 2019, and in 2021, ACIP recommended routine use of Dengvaxia for children aged 9–16 years with laboratory confirmation of previous DENV infection and living in areas where dengue is endemic. Dengvaxia is the first dengue vaccine recommended for use in the United States.

#### Safety and Efficacy

For children aged 9 to 16 years with evidence of previous dengue infection, Dengvaxia has an efficacy


of about 80% against the outcomes of symptomatic virologically confirmed dengue (VCD) followed over 25 months as well as hospitalization for dengue and severe dengue as defined by criteria set by the trial’s independent data monitoring committee and followed over 60 months (Table 3).<sup>105,106</sup> The efficacy by serotype mirrored its induction of a homotypic immune response<sup>101</sup> with highest protection against DENV-4 (89%), followed by DENV-3 (80%), and lowest against DENV-1 (67%) and DENV-2 (67%) (Table 3).<sup>106</sup> Protection against mortality could not be reported because there were no dengue-related deaths in the phase 3 trials.

The most frequently reported side effects (regardless of the dengue serostatus before vaccination) were headache (40%), injection site pain (32%), malaise (25%), asthenia (25%), and myalgia (29%) (n = 1333).<sup>108</sup> Serious adverse events (ie, life-threatening events, hospitalization, disability or permanent damage, and death) within 28 days were rare in both vaccinated participants (0.6%) and control participants (0.8%) and were not significantly different. At 6 months, fewer severe adverse events were reported in the vaccine (2.8%) than in the control arm (3.2%).<sup>108</sup>

Children who were seronegative for dengue at the time of vaccination had increased risk of severe illness on subsequent dengue infections. Risk of dengue-related hospitalization was approximately 1.5 times higher, and risk of severe dengue was approximately 2.5 times higher among seronegative children aged 9 to 16 years who were vaccinated than control participants over a 5-year period.<sup>106</sup>

#### Prevaccination Laboratory Testing

The requirement for a laboratory test before administration creates a unique challenge for Dengvaxia



**FIGURE 6**

Proposed mechanism of Dengvaxia efficacy based on prior dengue antigen exposure. Risk of severe disease is represented by color (low = green, medium = yellow, and high = red). Exposure to dengue antigens is represented by mosquito figure for wild-type exposure and by a syringe for Dengvaxia exposure. The first row shows an unvaccinated individual exposed to 4 different dengue serotypes in their life with highest risk for severe disease with second infection and low risk of severe disease in the third and fourth infection. The second row shows an individual without previous dengue exposure who receives Dengvaxia, which acts as a silent primary infection, and then has higher risk for severe disease upon their first exposure to wildtype dengue, the equivalent of the second exposure to dengue antigen. The third row shows an individual with previous wild-type infection who receives Dengvaxia which acts as a silent second dengue exposure with lower risk for severe disease in subsequent exposures to wild-type dengue.



**TABLE 3** Dengvaxia Efficacy by Outcome and by Serotype in Persons 9–16 Years Old with Evidence of Previous Dengue Virus Infection

Outcome	VE	95% CI
Virologically confirmed disease (all serotypes) <sup>a,105</sup>	81.9	67.2 to 90.0
By serotype <sup>a,105</sup>		
DENV-1	67.4	45.9 to 80.4
DENV-2	67.3	46.7 to 79.9
DENV-3	80.0	67.3% to 87.7
DENV-4	89.3	79.8% to 94.4
Hospitalization (all serotypes) <sup>b,106</sup>	79	69% to 86
Severe disease (all serotypes) <sup>b,106</sup>	84	63% to 93

Pooled vaccine efficacy data are from CYD14 and CYD15 (clinical trial registration: NCT01373281, NCT01374516). CI, confidence interval; VE, vaccine efficacy. Data are presented as percentages.

<sup>a</sup> Follow-up over 25 mo.

<sup>b</sup> Follow-up over 60 mo.

implementation. In areas with ongoing transmission of flaviviruses other than dengue, qualifying laboratory tests include a positive

NAAT or NS1 test performed during an episode of acute dengue or a positive result on prevaccination screening tests for serologic

**TABLE 4** Test Performance for a Dengue Prevaccination Screening Test in Different Seroprevalence Scenarios<sup>11</sup>

Seroprevalence in the Eligible Population (%)	Test Sensitivity (%)	Test Specificity (%)	PPV (%)	NPV (%)
30	60	95	84	85
30	70	95	86	88
30	75	95	87	90
30	80	95	87	92
30	90	95	89	96
30	60	98	93	85
30	70	98	94	88
30 <sup>a</sup>	75	98	94	90
30	80	98	94	92
30	90	98	95	96
50	60	95	92	70
50	70	95	93	76
50	75	95	94	79
50	80	95	94	83
50	90	95	95	90
50	60	98	97	71
50	70	98	97	77
50 <sup>a</sup>	75	98	97	80
50	80	98	98	83
50	90	98	98	91
60	60	95	95	61
60	70	95	95	68
60	75	95	95	72
60	80	95	96	76
60	90	95	96	86
60	60	98	98	62
60	70	98	98	69
60 <sup>a</sup>	75	98	98	72
60	80	98	98	77
60	90	98	99	87

NPV, negative predictive value; PPV, positive predictive value.

<sup>a</sup> CDC recommends that prevaccination screening tests that determine previous dengue infection have a minimum sensitivity of 75% and a minimum specificity of 98%. The recommendations also specify that the tests should be used in populations where they will achieve a positive predictive value (PPV) of  $\geq 90\%$  and a negative predictive value (NPV) of  $\geq 75\%$ . These rows demonstrate that tests with the same CDC recommended minimum sensitivity and specificity will have different PPV and NPV depending on the seroprevalence of the population in which they are used.

evidence of previous infection that meet specific performance characteristics. In areas without other ongoing flavivirus transmission, a positive dengue IgM assay during an episode of acute dengue is also considered a qualifying laboratory test.<sup>11</sup>

Prevaccination screening is critical because many DENV infections are asymptomatic or do not result in medical visits and testing. Thus, a significant proportion of previously infected individuals who could benefit from the vaccine will not be aware of or have laboratory documentation of their previous dengue infection.<sup>110–113</sup> One of the most challenging aspects in selecting a prevaccination test is defining benchmarks for test performance, as explored by several international working groups.<sup>114,115</sup> To reduce the risk of vaccinating someone without previous DENV infection, test specificity is a priority. Although test specificity and sensitivity are independent of seroprevalence, positive predictive value (PPV) and negative predictive value are dependent on seroprevalence and describe the likelihood of a true positive if a patient tests positive or the likelihood of a true negative if a patient tests negative (Table 4). In areas with moderate or low seroprevalence (eg, 30%–50%), high test specificity (>98%) is required to achieve a PPV of 90% and therefore reduce the risk of misclassifying seronegative individuals. In these settings, near-perfect specificity at the expense of sensitivity is preferred to minimize the risk of vaccinating a misclassified negative individual and subsequently increasing their risk of severe dengue. However, high-prevalence areas (eg, >60%) would benefit from a higher test sensitivity and more moderate specificity (eg, 95%), which would increase

identification of children who would benefit from the vaccine.<sup>116</sup>

Because dengue seroprevalence at age 9 to 16 years is estimated to be approximately 50% in Puerto Rico<sup>117,118</sup> (where most of the eligible population for Dengvaxia in the United States and its territories and freely associated states reside), the CDC recommends that tests have a minimum sensitivity of 75% and a minimum specificity of 98%. The recommendations also specify that the test performance in the population should achieve a PPV of  $\geq 90\%$  and a negative predictive value of  $\geq 75\%$ .<sup>11</sup> These test characteristics were used to model the risks and benefits of implementing Dengvaxia. Using Puerto Rico's population and an estimated seroprevalence of 50%,

the model found that Dengvaxia vaccination would avert approximately 4148 symptomatic disease cases and 2956 hospitalizations over a 10-year period. This implementation would also result in an additional 51 hospitalizations caused by vaccination of people without previous dengue infection who were misclassified by the screening test.<sup>119</sup> The most common cause of hospitalization among vaccinated children will be breakthrough disease because the vaccine is not 100% efficacious.

### TAK-003

TAK-003, developed by Takeda, consists of 2 doses given 3 months apart. The clinical trial population was primarily composed of children aged 4 to 16 years. At 18 months

after vaccination, vaccine efficacy was found to be 80.2% against VCD, which waned to 62.0% by 3 years after vaccination.<sup>120,121</sup> Efficacy against hospitalization for dengue remained higher, at 83.6% at 3 years after vaccination. Differences in efficacy were observed by history of previous dengue infection, with higher efficacy among persons with previous infection compared with those without previous infection (65.0%–54.3%), and by age, with higher efficacy in older children. In contrast to findings from Dengvaxia at 25 months, children who were seronegative at the time of TAK-003 vaccination did not show an overall increased risk for hospitalization and severe disease compared with the placebo group at 3 years, although efficacy varied by DENV serotype and an age effect could not be ruled out (Table 5).<sup>106,120</sup>

Efficacy against both VCD and hospitalization varied by serotype and corresponded to the homotypic antibody titers,<sup>102</sup> with highest efficacy against DENV-2 and lowest against DENV-3 and DENV-4. Among children without previous DENV infection, there was no observed efficacy for VCD against DENV-3 or DENV-4. In the safety analysis, the number of serious adverse events was similar between vaccine (2.9%) and placebo (3.5%) groups.

In March 2021, Takeda submitted TAK-003 to the European Medicines Agency for prevention of dengue from any DENV serotype among people aged 4 to 60 years.<sup>122</sup> The company will also be submitting filings to regulatory agencies in Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka, and Thailand during 2021 and has future plans to submit to the FDA.

**TABLE 5** TAK-003 Efficacy by Serostatus, Outcome, Serotype, and Age Group in Persons Aged 4–16 Years Over 36 Months of Follow-Up<sup>120</sup>

Outcome	VE	95% CI
Vaccinees with evidence of previous dengue virus infection (seropositives)		
Virologically confirmed disease (all serotypes)	65.0	58.9 to 70.1
Virologically confirmed disease by serotype		
DENV-1	56.2	43.7 to 66.0
DENV-2	83.4	76.4 to 88.3
DENV-3	52.3	36.6 to 64.2
DENV-4	60.7	16.0 to 81.6
Hospitalization (all serotypes)	86.0	78.4 to 91.0
Vaccinees with no evidence of previous dengue virus infection (seronegatives)		
Virologically confirmed disease (all serotypes)	54.3	41.9 to 64.1
Virologically confirmed disease by serotype		
DENV-1	43.5	21.5 to 59.3
DENV-2	91.9	83.6 to 96.0
DENV-3	–23.4	–125.3 to 32.4
DENV-4	–105.5	–867.5 to 56.4
Hospitalization (all serotypes)	77.1	58.6 to 87.3
Virologically confirmed disease by age group (all serotypes, serostatus combined)		
4–5 y	42.3	22.5 to 57.0
6–11 y	64.6	57.8 to 70.4
12–16 y	68.9	58.7 to 76.6
Hospitalization by age group (all serotypes, serostatus combined)		
4–5 y	50.6	–13.9 to 78.6
6–11 y	85.7	77.3 to 91.0
12–16 y	89.1	76.6 to 94.9

Vaccine efficacy data are from clinical trial NCT02747927. CI, confidence interval; VE, vaccine efficacy. Data presented as percentage.

### TV003

TV003 was developed by the National Institutes of Health and was formulated by selecting serotype-specific components that were determined to provide the most balanced safety and immunogenicity profile based on an evaluation of multiple monovalent and tetravalent candidates.<sup>123,124</sup> Because antibody titers failed to predict the efficacy of Dengvaxia, a human infection model was developed to assess the protective immunity induced by TV003 against DENV-2 challenge. Forty-eight volunteers were enrolled and randomized to receive TV003 (24) or placebo (24). Six months later, volunteers were administered a naturally attenuated DENV-2 challenge virus.<sup>125</sup> The primary efficacy endpoint was protection against detectable viremia after challenge. After challenge, DENV-2 was recovered by culture or reverse transcription-polymerase chain reaction (RT-PCR) from 100% of placebo recipients ( $n = 20$ ) and 0% of TV003 recipient ( $n = 21$ ) ( $P < .0001$ ). Postchallenge, rash was observed in 80% of placebo recipients compared with 0% of TV003 recipients ( $P < .0001$ ).

TV003 has been licensed to several manufacturers globally, including Merck & Co in the United States and the Instituto Butantan in Brazil. Phase 3 trials in Brazil are underway with efficacy and safety results expected in late 2022 (Clinical trial registration: NCT02406729).

### CONCLUSION AND FUTURE DIRECTIONS

Dengue is the most common arboviral disease worldwide and is projected to increase in range and global burden of disease. Although advancements in the field have

progressed incrementally for decades, the recent approval of Dengvaxia for routine use marks a major step forward for control and prevention efforts in the United States and paves the way for future dengue vaccines.

Dengvaxia has several complexities that necessitate future research, including the possibility of fewer doses in the initial schedule followed by booster doses in later years.<sup>30</sup> Because it is the first vaccine to require laboratory testing before administration, public-private partnerships to develop more specific, sensitive, and accessible tests or testing algorithms will be key to minimize vaccination of persons without previous DENV infection and maximize benefit to those with previous infection. Jurisdictions that wish to use Dengvaxia will need to gather seroprevalence data and ensure that prevaccination screening tests meet the requirements for positive and negative predictive values. Furthermore, behavioral science assessments to elicit community-level perceptions and concerns combined with health systems research on optimal “test-and-vaccinate” strategies will result in dengue vaccination programs that are well accepted, efficient, and tailored to individual communities.

TAK-003 and TV003 are in late-stage trials and could soon be approaching licensure. An indication for use in travelers would offer clinicians in nonendemic areas of the United States a prophylactic therapeutic option for their patients. While awaiting the approval of a vaccine with balanced serotype immunity, a mix-and-match strategy guided by differences in serotype-dominant immune responses in each vaccine

(TAK-003 followed by Dengvaxia, for example) could potentially lead to higher levels of protection against dengue, but it has yet to be evaluated for safety and efficacy in clinical trials.<sup>126</sup> For all 3 vaccines, studies evaluating efficacy against emerging DENV serotype variants will be important to assess long-term protection induced by the vaccine strains.<sup>10,127</sup>

Future vaccines against dengue could also benefit from the lessons learned from the COVID-19 pandemic, namely that new vaccine platform technologies plus political will can result in rapid development of safe and effective vaccines and that clear communication with the public is crucial to successful vaccine implementation.<sup>128-130</sup> Dengue vaccines based on an mRNA platform are already under investigation.<sup>131</sup>

Vaccines are a powerful new tool in our arsenal against dengue, but they are only 1 of many interventions, including novel vector control strategies, to control a virus with a complex epidemiology, immunopathogenesis, and clinical picture influenced by climate change, urbanization, poverty, and human migration. Clinicians should remain vigilant in recognizing and diagnosing patients with dengue, because early treatment remains the cornerstone for reducing morbidity and mortality. However, with the recent approval of Dengvaxia, we are 1 step closer on the path to dengue elimination and can expect exciting new developments in dengue interventions in the near future.

### ACKNOWLEDGMENT

We thank Ms Alexia E. Rodriguez, MPH, for her review of the manuscript.

## ABBREVIATIONS

ACIP: Advisory Committee on Immunization Practices  
ADE: antibody dependent enhancement  
CDC: Centers for Disease Control and Prevention  
DENV: dengue virus  
FDA: Food and Drug Administration  
IgM: immunoglobulin M  
NAAT: nucleic acid amplification test  
NS1: nonstructural protein 1  
PPV: positive predictive value  
PRNT: plaque reduction neutralization test  
VCD: virologically confirmed dengue  
WHO: World Health Organization

## REFERENCES

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. *Nature*. 2013;496(7446):504–507
2. Messina JP, Brady OJ, Golding N, et al. The current and future global distribution and population at risk of dengue. *Nat Microbiol*. 2019;4(9):1508–1515
3. Yang X, Quam MBM, Zhang T, Sang S. Global burden for dengue and the evolving pattern in the past 30 years. *J Travel Med*. 2021;28(8):taab146
4. San Martín JL, Brathwaite O, Zambrano B, et al. The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. *Am J Trop Med Hyg*. 2010;82(1):128–135
5. Pan American Health Organization. Dengue. Available at: <https://www.paho.org/data/index.php/en/mnu-topics/indicadores-dengue-en.html>. Accessed October 12, 2021
6. Dos Santos TH, Martin JLS, Castellanos LG, Espinal MA. Dengue in the Americas: Honduras' worst outbreak. *Lancet*. 2019;394(10215):2149
7. Wilder-Smith A. Risk of dengue in travelers: implications for dengue vaccination. *Curr Infect Dis Rep*. 2018;20(12):50
8. Schwartz E, Weld LH, Wilder-Smith A, et al; GeoSentinel Surveillance Network. Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997–2006. *Emerg Infect Dis*. 2008;14(7):1081–1088
9. Shihada S, Emmerich P, Thomé-Bolduan C, et al. Genetic diversity and new lineages of dengue virus serotypes 3 and 4 in returning travelers, Germany, 2006–2015. *Emerg Infect Dis*. 2017;23(2):272–275
10. Martínez DR, Yount B, Nivarthi U, et al. Antigenic variation of the dengue virus 2 genotypes impacts the neutralization activity of human antibodies in vaccinees. *Cell Rep*. 2020;33(1):108226
11. Paz-Bailey G, Adams L, Wong JM, et al. Dengue vaccine: recommendations of the advisory committee on immunization practices, United States, 2021. *MMWR Recomm Rep*. 2021;70(6):1–16
12. Sharp TM, Ryff KR, Santiago GA, Margolis HS, Waterman SH. Lessons learned from dengue surveillance and research, Puerto Rico, 1899–2013. *Emerg Infect Dis*. 2019;25(8):1522–1530
13. Rivera A, Adams LE, Sharp TM, Lehman JA, Waterman SH, Paz-Bailey G. Travel-associated and locally acquired dengue cases - United States, 2010–2017. *MMWR Morb Mortal Wkly Rep*. 2020;69(6):149–154
14. Centers for Disease Control and Prevention NCFaZIDN. Division of vector-borne diseases (DVBD), dengue: statistics and maps. Available at: <https://www.cdc.gov/dengue/statistics-maps/index.html>. Accessed October 18, 2021
15. Johnson TL, Haque U, Monaghan AJ, et al. Modeling the environmental suitability for *Aedes (Stegomyia) aegypti* and *Aedes (Stegomyia) albopictus* (Diptera: Culicidae) in the contiguous United States. *J Med Entomol*. 2017;54(6):1605–1614
16. Thomas DL, Santiago GA, Abeyta R, et al. Reemergence of dengue in southern Texas, 2013. *Emerg Infect Dis*. 2016;22(6):1002–1007
17. Kraemer MU, Sinka ME, Duda KA, et al. The global distribution of the arbovirus vectors *Aedes aegypti* and *Ae. albopictus*. *eLife*. 2015;4:e08347
18. Brunkard JM, Robles López JL, Ramirez J, et al. Dengue fever seroprevalence and risk factors, Texas-Mexico border, 2004. *Emerg Infect Dis*. 2007;13(10):1477–1483
19. Ramos MM, Mohammed H, Zielinski-Gutierrez E, et al; Dengue Serosurvey Working Group. Epidemic dengue and dengue hemorrhagic fever at the Texas-Mexico border: results of a household-based seroepidemiologic survey, December 2005. *Am J Trop Med Hyg*. 2008;78(3):364–369
20. Campbell LP, Luther C, Moo-Llanes D, Ramsey JM, Danis-Lozano R, Peterson AT. Climate change influences on global distributions of dengue and chikungunya virus vectors. *Philos Trans R Soc Lond B Biol Sci*. 2015;370(1665):20140135
21. Barrera R, Amador M, MacKay AJ. Population dynamics of *Aedes aegypti* and dengue as influenced by weather and human behavior in San Juan, Puerto Rico. *PLoS Negl Trop Dis*. 2011;5(12):e1378
22. Soneja S, Tsarouchi G, Lumbroso D, Tung DK. A review of dengue's historical and future health risk from a changing climate. *Curr Environ Health Rep*. 2021;8(3):245–265
23. Eder M, Cortes F, Teixeira de Siqueira Filha N, et al. Scoping review on vector-borne diseases in urban areas: transmission dynamics, vectorial capacity and co-infection. *Infect Dis Poverty*. 2018;7(1):90
24. Reiter P, Lathrop S, Bunning M, et al. Texas lifestyle limits transmission of dengue virus. *Emerg Infect Dis*. 2003;9(1):86–89
25. Abdul-Ghani R, Mahdy MAK, Al-Eryani SMA, et al. Impact of population displacement and forced movements on the transmission and outbreaks of *Aedes*-borne viral diseases: dengue as a model. *Acta Trop*. 2019;197:105066
26. Gubler DJ. Dengue, urbanization and globalization: the unholy trinity of the 21(st) Century. *Trop Med Health*. 2011;39(4 Suppl):3–11
27. Teixeira MG, Barreto ML, Costa MC, Ferreira LDA, Vasconcelos PFC, Cairncross S. Dynamics of dengue virus circulation: a silent epidemic in a complex urban area. *Trop Med Int Health*. 2002;7(9):757–762
28. Gubler DJ. Dengue and dengue hemorrhagic fever. *Clin Microbiol Rev*. 1998;11(3):480–496
29. Estallo EL, Carbajo AE, Grech MG, et al. Spatio-temporal dynamics of dengue

- 2009 outbreak in Córdoba City, Argentina. *Acta Trop*. 2014;136:129–136
30. Wilder-Smith A, Ooi E-E, Horstick O, Wills B. Dengue. *Lancet*. 2019;393(10169):350–363
  31. Simmons CP, Farrar JJ, Nguyen V, Wills B. Dengue. *N Engl J Med*. 2012;366(15):1423–1432
  32. Snow GE, Haaland B, Ooi EE, Gubler DJ. Review article: research on dengue during World War II revisited. *Am J Trop Med Hyg*. 2014;91(6):1203–1217
  33. Sabin AB. Research on dengue during World War II. *Am J Trop Med Hyg*. 1952;1(1):30–50
  34. Montoya M, Gresh L, Mercado JC, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. *PLoS Negl Trop Dis*. 2013;7(8):e2357
  35. Anderson KB, Gibbons RV, Cummings DAT, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. *J Infect Dis*. 2014;209(3):360–368
  36. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. *Yale J Biol Med*. 1970;42(5):311–328
  37. Kliks SC, Nimmannitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. *Am J Trop Med Hyg*. 1988;38(2):411–419
  38. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. *Nat Rev Microbiol*. 2007;5(7):518–528
  39. Fernández-García L, Angulo J, Ramos H, et al. The internal ribosome entry site of the *Dengue virus* mRNA is active when cap-dependent translation initiation is inhibited. *J Virol*. 2020;95(5):e01998-20
  40. Cervantes-Salazar M, Angel-Ambrocio AH, Soto-Acosta R, et al. Dengue virus NS1 protein interacts with the ribosomal protein RPL18: this interaction is required for viral translation and replication in Huh-7 cells. *Virology*. 2015;484:113–126
  41. Glasner DR, Puerta-Guardo H, Beatty PR, Harris E. The good, the bad, and the shocking: the multiple roles of dengue virus nonstructural protein 1 in protection and pathogenesis. *Annu Rev Virol*. 2018;5(1):227–253
  42. Durbin AP. Dengue vascular leak syndrome: insights into potentially new treatment modalities. *J Clin Invest*. 2019;129(10):4072–4073
  43. Weiskopf D, Angelo MA, de Azeredo EL, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. *Proc Natl Acad Sci USA*. 2013;110(22):E2046–E2053
  44. Zellweger RM, Eddy WE, Tang WW, Miller R, Shrestha S. CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. *J Immunol*. 2014;193(8):4117–4124
  45. Katzelnick LC, Gresh L, Halloran ME, et al. Antibody-dependent enhancement of severe dengue disease in humans. *Science*. 2017;358(6365):929–932
  46. Katzelnick LC, Harris E; Participants in the Summit on Dengue Immune Correlates of Protection. Immune correlates of protection for dengue: state of the art and research agenda. *Vaccine*. 2017;35(36):4659–4669
  47. Katzelnick LC, Narvaez C, Arguello S, et al. Zika virus infection enhances future risk of severe dengue disease. *Science*. 2020;369(6507):1123–1128
  48. Flasche S, Jit M, Rodríguez-Barraquer I, et al. The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): a model comparison study. *PLoS Med*. 2016;13(11):e1002181
  49. Sharp TM, Anderson KB, Katzelnick LC, et al. Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation. *Lancet Infect Dis*. 2022;22(2):e42–e51
  50. Grange L, Simon-Loriere E, Sakuntabhai A, Gresh L, Paul R, Harris E. Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections. *Front Immunol*. 2014;5:280
  51. Centers for Disease Control and Prevention. Dengue clinical case management clinician pocket guide. Available at: [https://www.cdc.gov/dengue/resources/DengueCheatSheet\\_ENG-P.pdf](https://www.cdc.gov/dengue/resources/DengueCheatSheet_ENG-P.pdf). Accessed November 8, 2021
  52. Regional Arboviral Disease Program. *Algorithms for the Clinical Management of Dengue Patients*. Washington D.C.: Pan American Health Organization (PAHO); 2020.
  53. Centers for Disease Control and Prevention. *CDC Yellow Book 2020: Health Information for International Travel*. New York: Oxford University Press; 2017
  54. Wills BA, Nguyen MD, Ha TL, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. *N Engl J Med*. 2005;353(9):877–889
  55. Lam PK, Tam DT, Diet TV, et al. Clinical characteristics of dengue shock syndrome in Vietnamese children: a 10-year prospective study in a single hospital. *Clin Infect Dis*. 2013;57(11):1577–1586
  56. Santiago GA, Vergne E, Quiles Y, et al. Analytical and clinical performance of the CDC real time RT-PCR assay for detection and typing of dengue virus. *PLoS Negl Trop Dis*. 2013;7(7):e2311
  57. Centers for Disease Control and Prevention. Dengue for Healthcare Providers: Testing Guidance. Available at: <https://www.cdc.gov/dengue/healthcare-providers/testing/testing-guidance.html>. Accessed June 30, 2021
  58. Hunsperger EA, Muñoz-Jordán J, Beltran M, et al. Performance of dengue diagnostic tests in a single-specimen diagnostic algorithm. *J Infect Dis*. 2016;214(6):836–844
  59. Munoz-Jordan JL. Diagnosis of Zika virus infections: challenges and opportunities. *J Infect Dis*. 2017;216(suppl\_10):S951–S956
  60. Lindsey NP, Staples JE, Powell K, et al. Ability to serologically confirm recent Zika virus infection in areas with varying past incidence of dengue virus infection in the United States and US territories in 2016. *J Clin Microbiol*. 2017;56(1):e01115–e01117
  61. Sharp TM, Fischer M, Muñoz-Jordán JL, et al. Dengue and Zika virus diagnostic testing for patients with a clinically

- compatible illness and risk for infection with both viruses. *MMWR Recomm Rep*. 2019;68(1):1–10
62. Food and Drug Administration K100534 InBios DENV detect IgM capture ELISA; evaluation of automatic class III designation. Available at: [https://www.accessdata.fda.gov/cdrh\\_docs/pdf10/K100534.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf10/K100534.pdf). Accessed November 1, 2021
  63. Food and Drug Administration (FDA). 510(k) substantial equivalence determination decision summary; K181473 InBios dengue virus NS1 antigen. 2018.
  64. Goncalves A, Peeling RW, Chu MC, et al. Innovative and new approaches to laboratory diagnosis of Zika and dengue: a meeting report. *J Infect Dis*. 2018;217(7):1060–1068
  65. Harapan H, Michie A, Sasmono RT, Imrie A. Dengue: a minireview. *Viruses*. 2020;12(8):829
  66. Centers for Disease Control and Prevention. Dengue Case Management. Available at: [https://www.cdc.gov/dengue/resources/dengue-clinician-guide\\_508.pdf](https://www.cdc.gov/dengue/resources/dengue-clinician-guide_508.pdf). Accessed October 21, 2021
  67. Nasir NH, Mohamad M, Lum LCS, Ng CJ. Effectiveness of a fluid chart in outpatient management of suspected dengue fever: a pilot study. *PLoS One*. 2017;12(10):e0183544
  68. Harris E, Pérez L, Phares CR, et al. Fluid intake and decreased risk for hospitalization for dengue fever, Nicaragua. *Emerg Infect Dis*. 2003;9(8):1003–1006
  69. Pan American Health Organization (PAHO). Self-learning course: clinical diagnosis and management of dengue (2021). Available at: <https://www.campusvirtualsp.org/en/course/self-learning-course-clinical-diagnosis-and-management-dengue-2021>. Accessed November 1, 2021
  70. Lee TH, Lee LK, Lye DC, Leo YS. Current management of severe dengue infection. *Expert Rev Anti Infect Ther*. 2017;15(1):67–78
  71. Lewis SR, Pritchard MW, Evans DJ, et al. Colloids versus crystalloids for fluid resuscitation in critically ill people. *Cochrane Database Syst Rev*. 2018;8(8):CD000567
  72. Pan American Health Organization. In: Bureau PAS, ed. *Dengue: Guidelines for Patient Care in the Region of the Americas*, 2nd ed. Washington, DC: Regional Office of the World Health Organization; 2016
  73. World Health Organization (WHO) and the Special Programme for Research and Training in Tropical Diseases. *Dengue: Guidelines for Diagnosis*. Geneva: Treatment, Prevention and Control; 2009
  74. Kalayanarooj S, Vaughn DW, Nimmannitya S et al. Early clinical and laboratory indicators of acute dengue illness. *J Infect Dis*. 1999;176(2):313–321
  75. Kabra SK, Verma IC, Arora NK, Jain Y, Kalra V. Dengue haemorrhagic fever in children in Delhi. *Bull World Health Organ*. 1992;70(1):105–108
  76. Centers for Disease Control and Prevention. Dengue case management for clinicians. Available at: <https://www.cdc.gov/dengue/healthcare-providers/treatment.html>. Accessed October 12, 2021
  77. Zhang F, Kramer CV. Corticosteroids for dengue infection. *Cochrane Database Syst Rev*. 2014;2014(7):CD003488
  78. Dimaano EM, Saito M, Honda S, et al. Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. *Am J Trop Med Hyg*. 2007;77(6):1135–1138
  79. Khan Assir MZ, Kamran U, Ahmad HI, et al. Effectiveness of platelet transfusion in dengue fever: a randomized controlled trial. *Transfus Med Hemother*. 2013;40(5):362–368
  80. Lye DC, Archuleta S, Syed-Omar SF, et al. Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial. *Lancet*. 2017;389(10079):1611–1618
  81. Ko YC, Chen MJ, Yeh SM. The predisposing and protective factors against dengue virus transmission by mosquito vector. *Am J Epidemiol*. 1992;136(2):214–220
  82. Manrique-Saide P, Che-Mendoza A, Barrera-Perez M, et al. Use of insecticide-treated house screens to reduce infestations of dengue virus vectors, Mexico. *Emerg Infect Dis*. 2015;21(2):308–311
  83. Sharp TM, Moreira R, Soares MJ, et al. Underrecognition of dengue during 2013 epidemic in Luanda, Angola. *Emerg Infect Dis*. 2015;21(8):1311–1316
  84. Kenneson A, Beltrán-Ayala E, Borbor-Cordova MJ, et al. Social-ecological factors and preventive actions decrease the risk of dengue infection at the household-level: results from a prospective dengue surveillance study in Machala, Ecuador. *PLoS Negl Trop Dis*. 2017;11(12):e0006150
  85. Ferede G, Tiruneh M, Abate E, et al. A serologic study of dengue in northwest Ethiopia: suggesting preventive and control measures. *PLoS Negl Trop Dis*. 2018;12(5):e0006430
  86. CDC. 2019. Dengue—prevent mosquito bites. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases (DVBD). Available at: <https://www.cdc.gov/dengue/prevention/prevent-mosquito-bites.html#:~:text=Use%20air%20conditioning%2C%20if%20available,%2C%20flowerpots%2C%20or%20trash%20containers>. Accessed October 10, 2021
  87. Waterman SH, Novak RJ, Sather GE, Bailey RE, Rios I, Gubler DJ. Dengue transmission in two Puerto Rican communities in 1982. *Am J Trop Med Hyg*. 1985;34(3):625–632
  88. Achee NL, Gould F, Perkins TA, et al. A critical assessment of vector control for dengue prevention. *PLoS Negl Trop Dis*. 2015;9(5):e0003655
  89. Moyes CL, Vontas J, Martins AJ, et al. Contemporary status of insecticide resistance in the major Aedes vectors of arboviruses infecting humans. *PLoS Negl Trop Dis*. 2017;11(7):e0005625
  90. Achee NL, Grieco JP, Vatandoost H, et al. Alternative strategies for mosquito-borne arbovirus control. *PLoS Negl Trop Dis*. 2019;13(1):e0006822
  91. McGraw EA, O'Neill SL. Beyond insecticides: new thinking on an ancient problem. *Nat Rev Microbiol*. 2013;11(3):181–193
  92. Hilgenboecker K, Hammerstein P, Schlattmann P, Telschow A, Werren JH. How many species are infected with Wolbachia?—A statistical analysis of current data. *FEMS Microbiol Lett*. 2008;281(2):215–220
  93. O'Connor L, Plichart C, Sang AC, Brelsfoard CL, Bossin HC, Dobson SL. Open release of male mosquitoes infected with a

- wolbachia biopesticide: field performance and infection containment. *PLoS Negl Trop Dis*. 2012;6(11):e1797
94. Hoffmann AA, Ross PA, Rašić G. Wolbachia strains for disease control: ecological and evolutionary considerations. *Evol Appl*. 2015;8(8):751–768
  95. Crawford JE, Clarke DW, Criswell V, et al. Efficient production of male Wolbachia-infected *Aedes aegypti* mosquitoes enables large-scale suppression of wild populations. *Nat Biotechnol*. 2020; 38(4):482–492
  96. Beebe NW, Pagendam D, Trewin BJ, et al. Releasing incompatible males drives strong suppression across populations of wild and Wolbachia-carrying *Aedes aegypti* in Australia. *Proc Natl Acad Sci USA*. 2021;118(41):e2106828118
  97. Hoffmann AA, Montgomery BL, Popovici J, et al. Successful establishment of Wolbachia in *Aedes* populations to suppress dengue transmission. *Nature*. 2011;476(7361):454–457
  98. O'Neill SL, Ryan PA, Turley AP, et al. Scaled deployment of Wolbachia to protect the community from dengue and other *Aedes* transmitted arboviruses. *Gates Open Res*. 2019;2:36
  99. Utarini A, Indriani C, Ahmad RA, et al; AWED Study Group. Efficacy of Wolbachia-infected mosquito deployments for the control of dengue. *N Engl J Med*. 2021;384(23):2177–2186
  100. Popovici J, Moreira LA, Poinsgnon A, Iturbe-Ormaetxe I, McNaughton D, O'Neill SL. Assessing key safety concerns of a Wolbachia-based strategy to control dengue transmission by *Aedes* mosquitoes. *Mem Inst Oswaldo Cruz*. 2010;105(8):957–964
  101. Henein S, Swanstrom J, Byers AM, et al. Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue-exposed individuals. *J Infect Dis*. 2017;215(3):351–358
  102. White LJ, Young EF, Stoops MJ, et al. Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003). *PLoS Negl Trop Dis*. 2021;15(3):e0009258
  103. Nivarthi UK, Swanstrom J, Delacruz MJ, et al. A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans. *Nat Commun*. 2021;12(1):1102
  104. Villar L, Dayan GH, Arredondo-García JL, et al; CYD15 Study Group. Efficacy of a tetravalent dengue vaccine in children in Latin America. *N Engl J Med*. 2015;372(2):113–123
  105. Hadinegoro SR, Arredondo-García JL, Capeding MR, et al; CYD-TDV Dengue Vaccine Working Group. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. *N Engl J Med*. 2015;373(13):1195–1206
  106. Sridhar S, Luedtke A, Langevin E, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. *N Engl J Med*. 2018;379(4):327–340
  107. Halstead SB, Deen J. The future of dengue vaccines. *Lancet*. 2002;360(9341):1243–1245
  108. Dengvaxia [package insert]. Swiftwater, PA: Sanofi; 2019.
  109. Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. *Nat Rev Microbiol*. 2016;14(1):45–54
  110. Bonaparte M, Huleatt J, Hodge S, et al. Evaluation of dengue serological tests available in Puerto Rico for identification of prior dengue infection for pre-vaccination screening. *Diagn Microbiol Infect Dis*. 2020;96(3):114918
  111. Bonaparte M, Zheng L, Garg S, et al. Evaluation of rapid diagnostic tests and conventional enzyme-linked immunosorbent assays to determine prior dengue infection. *J Travel Med*. 2019;26(8): taz078
  112. DiazGranados CA, Bonaparte M, Wang H, et al. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials. *Lancet Infect Dis*. 2021;21(4):529–536
  113. Luo R, Fongwen N, Kelly-Cirino C, Harris E, Wilder-Smith A, Peeling RW. Rapid diagnostic tests for determining dengue serostatus: a systematic review and key informant interviews. *Clin Microbiol Infect*. 2019;25(6):659–666
  114. Fongwen N, Wilder-Smith A, Gubler DJ, et al. Target product profile for a dengue pre-vaccination screening test. *PLoS Negl Trop Dis*. 2021;15(7):e0009557
  115. Wilder-Smith A, Smith PG, Luo R, et al. Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: a meeting report. *Vaccine*. 2019;37(36):5137–5146
  116. Flasche S, Smith PG. Sensitivity and negative predictive value for a rapid dengue test. *Lancet Infect Dis*. 2019;19(5):465–466
  117. Argüello DF, Tomashek KM, Quiñones L, et al. Incidence of dengue virus infection in school-aged children in Puerto Rico: a prospective seroepidemiologic study. *Am J Trop Med Hyg*. 2015;92(3):486–491
  118. L'Azou M, Assoukpa J, Fanouillere K, et al. Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014). *Trans R Soc Trop Med Hyg*. 2018;112(4):158–168
  119. Paz-Bailey G. Dengue vaccine draft recommendations using the evidence to recommendation framework. Advisory Committee on Immunization Practices (ACIP); 2021; Atlanta, GA.
  120. Rivera L, Biswal S, Sáez-Llorens X, et al; TIDES study group. Three years efficacy and safety of Takeda's dengue vaccine candidate (TAK-003). *Clin Infect Dis*. 2021;ciab864
  121. Biswal S, Reynales H, Saez-Llorens X, et al; TIDES Study Group. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. *N Engl J Med*. 2019;381(21):2009–2019
  122. Takeda Pharmaceutical Company Limited. Takeda begins regulatory submissions for dengue vaccine candidate in EU and dengue-endemic countries. Available at: <https://www.takeda.com/newsroom/newsreleases/2021/takeda-begins-regulatory-submissions-for-dengue-vaccine-candidate-in-eu-and-dengue-endemic-countries/>. Accessed October 18, 2021
  123. Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. *Vaccine*. 2011;29(42):7242–7250
  124. Durbin AP, Kirkpatrick BD, Pierce KK, et al. A single dose of any of four different live attenuated tetravalent dengue

- vaccines is safe and immunogenic in flavivirus-naïve adults: a randomized, double-blind clinical trial. *J Infect Dis.* 2013;207(6):957–965
125. Kirkpatrick BD, Whitehead SS, Pierce KK, et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. *Sci Transl Med.* 2016;8(330):330ra36
  126. Wilder-Smith A. Dengue vaccine development by the year 2020: challenges and prospects. *Curr Opin Virol.* 2020;43: 71–78
  127. Juraska M, Magaret CA, Shao J, et al. Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. *Proc Natl Acad Sci USA.* 2018;115(36):E8378–E8387
  128. Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation [published correction appears in *Nat Rev Drug Discov.* 2021;20(11):880]. *Nat Rev Drug Discov.* 2021;20(11):817–838
  129. Excler J-L, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious diseases. *Nat Med.* 2021; 27(4):591–600
  130. Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. *Nat Med.* 2021;27(2):225–228
  131. Wollner CJ, Richner JM. mRNA vaccines against flaviviruses. *Vaccines (Basel).* 2021;9(2):148
  132. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. *Lancet.* 2012;380(9853):1559–1567
  133. Huang CY-H, Butrapet S, Tsuchiya KR, Bhamarapavati N, Gubler DJ, Kinney RM. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. *J Virol.* 2003;77(21): 11436–11447